Midazolam α-hydroxylation by human liver microsomes in vitro: Inhibition by calcium channel blockers, itraconazole and ketoconazole

Pharmacology and Toxicology

Volumn 85, Issue 4, 1999, Pages 157-161

  Wang, Jun Sheng ^a   Wen, Xia ^a   Backman, Janne T ^a   Taavitsainen, Päivi ^b   Neuvonen, Pertti J ^a   Kivistö, Kari T ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b UNIVERSITY OF OULU   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; CYTOCHROME; DILTIAZEM; HYDROXYITRACONAZOLE; ISRADIPINE; ITRACONAZOLE; KETOCONAZOLE; MIBEFRADIL; MIDAZOLAM; NIFEDIPINE; VERAPAMIL;

ARTICLE; CHEMICAL REACTION; CONCENTRATION RESPONSE; HUMAN; HUMAN TISSUE; HYDROXYLATION; INHIBITION KINETICS; LIVER MICROSOME; PRIORITY JOURNAL;

EID: 0032859247     PISSN: 09019928     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0773.1999.tb00085.x     Document Type: Article

References (32)

1. Back, D. J. & J. F. Tjia: Comparative effects of the antimycotic drugs ketoconazole, fluconazole, itraconazole and terbinafine on the metabolism of cyclosporin by human liver microsomes. Brit. J. Clin. Pharmacol. 1991, 32, 624-626.
2. Backman, J. T., K. T. Olkkola, K. Aranko, J.-J. Himberg & P. J. Neuvonen: Dose of midazolam should be reduced during diltiazem and verapamil treatments. Brit. J. Clin. Pharmacol. 1994, 37, 221-225.
3. Boobis, A. R.: Prediction of inhibitory drug-drug interactions by studies in vitro. In: Advances in drug metabolism in man. Eds.: G. M. Pacifici & G. N. Fracchia. Office for Official Publications or the European Communities, Luxembourg, 1995, pp. 515-539.
4. Bourrie, M., V. Meunier, Y. Berger & G. Fabre: Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes. J. Pharmacol. Exp. Therap. 1996, 277, 321-332.
5. Endresen, L., S. Bergan, H. Holdaas, T. Pran, B. Sinding-Larsen & K. J. Berg: Lack of effect of the calcium antagonist isradipine on cyclosporine pharmacokinetics in renal transplant patients. Ther. Drug Monit. 1991, 13, 490-495.
6. Gascon, M.-P. & P. Dayer: In vitro forecasting of drugs which may interfere with the biotransformation of midazolam. Eur. J. Clin. Pharmacol. 1991, 41, 573-578.
7. Gorski, J. C., S. D. Hall, D. R. Jones, M. Vanden Branden & S. A. Wrighton: Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily. Biochem. Pharmacol. 1994, 47, 1643-1653.
8. Ha, H. R., K. M. Rentsch, J. Kneer & D. J. Vonderschmitt: Determination of midazolam and its α-hydroxy metabolite inhuman plasma and urine by high-performance liquid chromatography. Ther. Drug Monit. 1993, 15, 338-343.
9. Heykants, J., A. Van Peer, V. Van de Velde, P. Van Rooy, W. Meuldermans, K. Lavrijsen, R. Woestenborghs, J. Van Cutsem & G. Cauwenbergh: The clinical pharmacokinetics of itraconazole: an overview. Mycoses 1989, 32 (Suppl. 1), 67-87.
10. Höglund, P. & L.-G. Nilsson: Pharmacokinetics of diltiazem and its metabolites after repeated multiple-dose treatments in healthy volunteers. Ther. Drug Monit. 1989, 11, 543-550.
11. Kivistö, K. T., T. S. Lamberg, T. Kantola & P. J. Neuvonen: Plasma buspirone concentrations are greatly increased by erythromycin and itraconazole. Clin. Pharmacol. Therap. 1997, 62, 348-354.
12. Kleinbloesem, C. H., P. van Brummelen & D. D. Breimer: Nifedipine. Relationship between pharmacokinetics and pharmacodynamics. Clin. Pharmacokin. 1987, 12, 12-29.
13. Kosuge, K., M. Nishimoto, M. Kimura, K. Umemura, M. Nakashima & K. Ohashi: Enhanced effect of triazolam with diltiazem. Brit. J. Clin. Pharmacol. 1997, 43, 367-372.
14. Kronbach, T., D. Mathys, M. Umeno, F. J. Gonzalez & U. A. Meyer: Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. Mol. Pharmacol. 1989, 36, 89-96.
15. Lamberg, T. S., K. T. Kivistö & P. J. Neuvonen: Effects of verapamil and diltiazem on the pharmacokinetics and pharmacodynamics of buspirone. Clin. Pharmacol. Therap. 1998, 63, 640-645.
16. Lukkari, E., P. Taavitsainen, A. Juhakoski & O. Pelkonen: Cytochrome P450 specificity of metabolism and interactions of oxybutynin in human liver microsomes. Pharmacology & Toxicology 1998, 82, 161-166.
17. Mandema, J. W., B. Tuk, A. L. van Steveninck, D. D. Breimer, A. F. Cohen & M. Danhof: Pharmacokinetic-pharmacodynamic modeling of the central nervous system effects of midazolam and its main metabolite alpha-hydroxymidazolam in healthy volunteers. Clin. Pharmacol. Therap. 1992, 51, 715-728.
18. Olkkola, K. T., J. T. Backman & P. J. Neuvonen: Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. Clin. Pharmacol. Therap. 1994, 55, 481-485.
19. Pelkonen, O., J. Mäenpää, P. Taavitsainen, A. Rautio & H. Raunio: Inhibition and induction of human P450 (CYP) enzymes. Xenobiotica 1998, 28, 1203-1253.
20. Po, A. L. & W. Y. Zhang: What lessons can be learnt from withdrawal of mibefradil from the market? Lancet 1998, 351, 1829-1830.
21. Schlanz, K. D., S. A. Myre & M. B. Bottorff: Pharmacokinetic interactions with calcium channel antagonists (Part II). Clin. Pharmacokin. 1991, 21, 448-460.
22. Schmassmann-Suhijar, D., R. Bullingham, R. Gasser, J. Schmutz & W. E. Haefeli: Rhabdomyolysis due to interaction of simvastatin with mibefradil. Lancet 1998, 351, 1929-1930.
23. Sutton, D., A. M. Butler, L. Nadin & M. Murray: Role of CYP3A4 in human hepatic diltiazem N-demethylation: inhibition of CYP3A4 activity by oxidized diltiazem metabolites. J. Pharmacol. Exp. Therap. 1997, 282, 294-300.
24. Thummel, K. E., D. D. Shen, T. D. Podoll, K. L. Kunze, W. F. Trager, P. S. Hartwell, V. A. Raisys, C. L. Marsh, J. P. McVicar, D. M. Barr, J. D. Perkins & R. L. Carithers, Jr.: Use of midazolam as a human cytochrome P450 3A probe: I. In vitro-in vivo correlations in liver transplant patients. J. Pharmacol. Exp. Therap. 1994, 271, 549-556.
25. Tsao, S. C., T. H. Dickinson & D. R. Abernethy: Metabolite inhibition of parent drug biotransformation. Studies of diltiazem. Drug Metab. Dispos. 1990, 18, 180-183.
26. Tse, F. L. S. & J. M. Jaffe: Pharmacokinetics of PN 200-110 (isradipine), a new calcium antagonist, after oral administration in man. Eur. J. Clin. Pharmacol. 1987, 32, 361-365.
27. Varhe, A., K. T. Olkkola & P. J. Neuvonen: Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol. Therap. 1994, 56, 601-607.
28. Varhe, A., K. T. Olkkola & P. J. Neuvonen: Diltiazem enhances the effects of triazolam by inhibiting its metabolism. Clin. Pharmacol. Therap. 1996, 59, 369-375.
29. Vernillet, L., B. Bourbigot, J. P. Codet, L. Le Saux, M. C. Moal & J. F. Morin: Lack of effect of isradipine on cyclosporin pharmacokinetics. Fund. Clin. Pharmacol. 1992, 6, 367-374.
30. von Moltke, L. L., D. J. Greenblatt, J. Schmider, S. X. Duan, C. E. Wright, J. S. Harmatz & R. I. Shader: Midazolam hydroxylation by human fiver microsomes in vitro: inhibition by fluoxetine, norfluoxetine, and by azole antifungal agents. J. Clin. Pharmacol. 1996, 36, 783-791.
31. von Moltke, L. L., D. J. Greenblatt, J. Schmider, C. E. Wright, J. S. Harmatz & R. I. Shader: In vitro approaches to predicting drug interactions in vivo. Biochem. Pharmacol. 1998, 55, 113-122.
32. Wrighton, S. A. & B. J. Ring: Inhibition of human CYP3A catalyzed 1′-hydroxy midazolam formation by ketoconazole, nifedipine, crythromycin, cimetidine, and nizatidine. Pharm. Res. 1994, 11, 921-924.